Target Selector™ assay kits enable assay developers to leverage Biocept's patented, high-sensitivity technology for the detection of key actional oncogene mutations from both tissue biopsies and blood for liquid biopsy uses SAN DIEGO , April 28, 2020 /PRNewswire/ -- Biocept, Inc .
SAN DIEGO , April 20, 2020 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the availability of
SAN DIEGO , April 14, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, today
Company to provide FDA-approved for EUA testing in its San Diego lab to assist physician clients in the fight against the coronavirus pandemic SAN DIEGO , April 9, 2020 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide
Expands global intellectual property portfolio for highly sensitive methods of detecting cancer biomarkers in circulating tumor DNA (ctDNA) and other genetic alterations of interest; increases Biocept's total patent awards for technologies used in molecular diagnostics to 39 SAN DIEGO , April 9,
Expands Biocept's intellectual property globally for methods of detecting rare mutations, including cancer biomarkers associated with circulating tumor DNA (ctDNA) SAN DIEGO , April 2, 2020 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed
Contract with second IPA serving California expands patient access to Biocept's Target Selector™ liquid biopsy testing for the management of patients diagnosed with cancer SAN DIEGO , March 26, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests
- Fourth quarter revenues reached a record $1.8 million, up 108% over the fourth quarter of 2018 and up 17% over the third quarter of 2019 - Fourth quarter commercial revenues increased 94% over the fourth quarter of 2018 and increased 11% over the third quarter of 2019 - Fourth quarter cost of
SAN DIEGO , March 18, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will release financial
SAN DIEGO , March 9, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the publication of clinical data
